Complications of dsngle-port robotic radical prostatectomy: A multi-institutional report from the Single-Port Advanced Research Consortium (SPARC)
Recommended Citation
Soputro N, Chavali JS, Ferguson EL, Ramos-Carpinteyro R, Calvo RS, Nguyen J, Moschovas MC, Wilder S, Okhawere K, Sanchez De La Rosa R, Saini I, Peabody JO, Badani KK, Rogers CG, Joseph J, Nix JW, Patel V, Stifelman MD, Ahmed M, Crivellaro S, Kim M, Kaouk JH. Complications of dsngle-port robotic radical prostatectomy: A multi-institutional report from the Single-Port Advanced Research Consortium (SPARC). Eur Urol Open Sci 2023; 55:S82-S83.
Document Type
Conference Proceeding
Publication Date
9-1-2023
Publication Title
Eur Urol Open Sci
Abstract
Introduction & Objectives: Following its introduction, recent years have seen the increasing utility of the purpose-built Single-Port (SP) robotic platform for varying approaches of robotic radical prostatectomy (RARP). Despite earlier series demonstrating favourable perioperative outcomes, there remains a paucity of evidence highlighting the morbidity of these procedures. Hence, this study sought to evaluate the perioperative complication following different approaches of SP-RARP using a multi-institutional database. Materials & Methods: A retrospective review was performed on the prospectively maintained, Institutional Review Board (IRB)-approved Single-Port Advanced Research Consortium (SPARC) database. All patients who underwent transperitoneal (TP), extraperitoneal (EP), and transvesical (TV) SP-RARP by 11 surgeons across 9 centers between 2019 and 2022 were included. The rates and reasons for the 90-day postoperative complication and readmission were analyzed for each surgical approach separately. Results: A total of 1103 patients were identified, which included 244, 712, and 147 patients who had TP, EP, and TV SP-RARP, respectively. Intraoperative complications were reported in five patients (0.4%), all of whom belonged to the TP cohort. Postoperative complications were noted in 143 patients (13%) with the majority being minor complications (Clavien-Dindo grade ≤2). The incidence of non-urological complications were significantly lower in the TV cohort (TP 8.2% vs. EP 6.3% vs. TV 3.4%, p = <0.05). The 90-day readmission rate was 3.9%. [Figure presented] Conclusions: SP-RARP provided a safe and effective addition to the repertoire of minimally-invasive surgical management for prostate cancer with a relatively low risk of 90-day postoperative complication and readmission. The varying surgical approaches were associated with different complication profiles, with markedly reduced non-urological complications following the more localized transvesical access.
Volume
55
First Page
S82
Last Page
S83
